The drug pipeline for amyotrophic lateral sclerosis (ALS) has expanded significantly in the last decade, with several different types of molecules and mechanisms starting to come into play. Among these include Amylyx’s AMX0144, an…
Clinical Perspectives on Promising Phase 1 Data of CAPN2-Targeting Therapy AMX0114 for ALS | NeurologyLive
